Paul Conyngham, an Australian tech entrepreneur who emphasizes that he is "not a biologist," used ChatGPT and Grok to design a personalized mRNA cancer vaccine for his dog Rosie. That story led him to found a startup called Gamgee, which sells personalized mRNA cancer vaccines for dogs.
What Gamgee offers and its backing
Gamgee says it accepts cases globally, has backing from Y Combinator, and promises a "vaccine in hand" in about four weeks. The company has also stated an ambition to eventually expand toward human treatments.
Why the outcome is uncertain
Reporting indicates that the evidence presented so far rests on a single case: Rosie. The Verge reported that Rosie received another therapy at the same time, meaning her subsequent improvement cannot be definitively attributed to the vaccine Gamgee provided. Researchers note that a sample size of one does not establish causation.
The role of AI and expert criticism
AI functions in the story both as a selling point and as a shield: it is presented as the tool that designed the vaccine, while the founder’s non-expert status can be used to deflect technical scrutiny. Observers warn that the narrative over-credits AI and minimizes the contributions of human scientists and technicians who perform laboratory work, manufacturing, and clinical evaluation.
Key takeaway
The case illustrates how a compelling personal narrative and the inclusion of "AI" can accelerate a startup's profile. At the same time, critics emphasize that the evidence is limited (n=1), causation is unproven, and ambitious claims about human applications demand rigorous, controlled testing.
Open questions and next steps
Questions remain about Gamgee’s clinical evidence, regulatory compliance, and how safety and efficacy will be demonstrated at scale. Until controlled studies and independent data are available, the company’s promises should be evaluated with caution.
